OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development

MT Newswires · 2d ago
02:38 AM EST, 12/08/2025 (MT Newswires) -- OSE Immunotherapeutics (OSE.PA) amended its partnership deal with US-based pharmaceutical company AbbVie (ABBV.VI) for the development of the chronic and severe inflammation drug candidate ABBV-230. Under the amended deal, the French biotechnology company regained control over the early-stage development of the drug, while AbbVie will have control over the future development and commercialization after the completion of phase 1, according to a Monday release. OSE Immunotherapeutics agreed to surrender the anticipated milestone payment linked to the initiation of the phase 1 clinical study. However, it would receive milestone payments if AbbVie advances the candidate beyond phase 1.